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MRangiography.
What about the usefulness of CT in patients with stroke? Figure 3
exhibits the images of a patient with severe headache. Figure 3
exhibits abnormally high density images of the left thalamus and
left lateral ventricle. The patient is diagnosed with acute cerebral
hemorrhage. CT can demonstrate acute hemorrhage so clearly.
A CT scanner is shaped like a doughnut. Contrast material is
used in some kinds of diseases. A CT scan can diagnose a variety of
common and uncommon conditions in the physical body. Today,
modern CT scanners can move quickly and can take images of a
patient in well under a minute.
CT scanners have an x-ray tube and detectors are set inside the
CT scanners directly opposite each other. The x-ray tube and
detectors continuously spin around the patient while scanning. In
some disease conditions, Iodine contrast material is intravenously
injected to evaluate tumor vascularity, vessel disease, such as
aneurysm and many other conditions. In this situation, the nurse
inserts a small catheter into the patient’s arm vein and contrast
media is injected. The Radiology technologist scans and recon-
structs many images. Both the nurse and the technologist care for
the patient during the entire examination. One caution when using
contrast media is to check the patient’s renal function as these are
excreted through the kidneys in the form of urine.
Figure 4 shows three CT images signifying hepatocellular carci-
noma (HCC). It is difficult to pick up the tumor without contrast
media, but HCC shows contrast enhancement and is clearly
Fig.1 Pancreatic cancer
Fig.2 Acute cerebral infarction. Right middle artery stenosis.
Fig.4 Hepatocellular carcinoma
Fig.3 Hemorrhage in thalamus
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demonstrated as high density on the early phase of dynamic CT
image.
Figure 5 shows images of the lung cancer patient. This was a 60-
year old male patient with an abnormal lesion on the left lung
found on chest x-ray examination. The tumor was located at the left
lung upper lobe, size 3.9 cm in diameter, attached to the chest
wall, thereby the suspicion of invasion to the chest wall. With het-
erogeneous contrast enhancement, this showed a lesion consistent
with necrosis or a degenerative change. After scanning, Radiology
technologists produced many kinds of 3D-images. Figure 5-c,d
are 3D-images of the left lung. The red vessel is the pulmonary
artery, blue one is the pulmonary vein, and the light green is the
trachea and bronchus. And purple section is the lung cancer.
Anatomical location of the lung cancer, relationship between the
tumor and vessels, and bronchus are clearly visualized and allows
observation of the tumor from any directions.
Figure 5-d is called virtual bronchoscopy imagery. This image
gives much information prior to the bronchoscopy procedure and
preoperative planning. It illuminates the best way to approach the
tumor. Evaluation of the tumor can use both virtual bronchoscopy
and 3D-image movie. To produce these images, do not require
additional radiation exposure. The reconstruction time is about a
minute. This patient had FDG-PET/CT scan for further examina-
tion.
Clinical indications of FDG-PET in Oncology
FDG is the abbreviation for fluoro-deoxy glucose, an analogue of
glucose containing a positron-emitting radioactive isotope, fluorine-
18, substituted for the normal hydroxyl group at the 2’ position.
PET is the abbreviation of positron-emission tomography. Clinical
indications of FDG-PET in oncology focus on the initial diagnosis /
staging and follow up as re-staging. These factors are critical
information in order to select the best treatment option such as
surgery, chemotherapy, radiation therapy and their combinations.
FDG-PET is useful to detect the recurrence or metastasis after
some treatment, and to monitor the treatment effect such as che-
motherapy for malignant lymphoma. FDG-PET has an advantage
in differentiating malignant lesion from benign. Malignant tumor
needs much more glucose compared to benign lesion. The patient is
asked to fast for at least six hours to avoid exercise on the day
before PET and if the patient is diabetic, to skip treatment for
diabetes mellitus on the day of the examination. Before FDG
injection, the blood glucose level is examined. The presence of a
high glucose level (150 mg/dl) may lead to underestimation of
the lesion.
Physiology of FDG Uptake
After FDG injection, the patient rests on a bed or sofa for one
hour. During this resting period, the FDG gradually accumulates
in normal organs and in the disease sites with high glucose uptake.
Both glucose and FDG enter the cell via the glucose transporter
expressed on the cell membranes and are phosphorylated by
hexokinase. Glucose-6-phosphate is metabolized to energy via
metabolic pathways. However, FDG is not metabolized from
FDG-6-P and stays in the cells. This is called metabolic trapping.
FDG is a glucose analogue, so it is physiologically taken up by
tissues such as the brain, heart, liver and so, and is excreted in the
urine. Malignant lesions require more glucose than normal tissues,
and exhibit more intense FDG uptake as a result. Inflammatory
lesions also utilize more glucose than normal tissues, and inflam-
mation and malignancy must be differentiated in clinical practice,
but sometimes it is difficult.
After voiding, the patient goes into the scan room and lies on the
couch. The scanner moves toward the patient. This part shaped
like a donut is the CT scanner, and the square shaped part is the
PET scanner. The scan starts with a localized image, and the CT
imaging follows. The CT part takes less than 1 min. The PET scan
follows the CT and takes about 20 min. Both CT and PET scans are
obtained under free-breathing conditions, and the total examina-
tion time is less than 30 min.
Determining and Describing the Imagery
PET/CT machine is a hybrid system comprising a PET scanner
and CT set in line with the scanner. Both biological and morpho-
logical information during a single session can be obtained and can
the two images can be fused on the monitor to more comprehen-
sively understand the location and activity of the lesion. Benign
lesion utilizes less glucose than malignant lesion, showing faint to
moderate FDG uptake. Both glucose metabolism and morphologic
findings of this nodule in a single image (PET/CT fusion image)
can be visualized. FDG-PET is a powerful tool to differentiate
malignant from benign.
As to the imagery produced by PET/CT, the left lung cancer of
the aforementioned patient showed very intense FDG uptake and
bilateral hilar lymph nodes were shown as bright spots. No other
distant images suggesting metastases were suggested. However,
physiological brain high uptake of glucose may mask abnormal
lesions such as brain metastasis, therefore, it is important to
include brain MRI with contrast agent. In lung cancer, the tumor
can show very intense FDG uptake with SUVmax22.1. SUV is an
abbreviation of standardized uptake value, and the larger the
number, it signifies that the glucose metabolism has increased
dramatically. Intense uptake is appreciated as malignant. However,
when using the gadolinium-enhanced MRI, no brain metastasis
was evident.
Summary
Correct diagnosis and tumor staging with the combination of
some clinical imaging examinations such as CT, FDG-PET and
brain MRI can be reached for the purpose of determining accurate
diagnosis and prognosis of patient condition. Described were the
utilization of clinical imaging technologies for the diagnoses and
appropriate treatments of tumor conditions. The focus of this paper
was to elucidate the types and use of clinical imaging technolo-
gies, with a focus on CT, MRI and FDG-PET. At the Tokushima
University Hospital, the radiology team does its best to support
patient care through the competent use of advancing clinical
imaging technologies in order to know persons more fully as
persons.
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